Clinical trials: HIV Infected Individuals
HIV Infections
ATV/Ritonavir Nevirapine Interaction (USPAC)
Open-Label, multiple-dose, drug interaction study to assess the effect of nevirapine on the pharmacokinetics of atazanavir in HIV-infected individuals.
- Trial name
- NCT00162149
- Testing
- Nevirapine, Nevirapine + Atazanavir/Ritonavir, Atazanavir + Ritonavir
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
HIV
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect…
- Trial name
- NCT01003990
- Testing
- Atazanavir, Atazanavir/Ritonavir, Tenofovir/Emtricitabine
- Where
- 88 sites in United States, Argentina and 23 more
- Volunteers
- 710 people
- Sponsor
- Bristol-Myers Squibb
Candidiasis, Oral, HIV Infections
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients…
- Trial name
- NCT00002431
- Testing
- Chlorhexidine gluconate
- Where
- 5 sites in United States
- Sponsor
- Procter and Gamble
HIV Infections
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients.
- Trial name
- NCT00002401
- Testing
- Indinavir sulfate, Delavirdine mesylate, Lamivudine
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Pharmacia and Upjohn
HIV -1 Infection
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry.
- Trial name
- VISTA (NCT07215468)
- Testing
- TMB-365, TMB-380, Baseline ART
- Where
- 10 sites in United States
- Volunteers
- 88 people
- Sponsor
- TaiMed Biologics Inc.
HIV Infections
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3
To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
- Trial name
- NCT00002123
- Testing
- Delavirdine mesylate, Didanosine
- Where
- 84 sites in United States, Puerto Rico
- Sponsor
- Pharmacia and Upjohn
HIV Infections
A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)
The use of a Bioject 2000 needle free injection device (NFID) and a compressed immunization schedule will be safely tolerated and will augment the immunogenicity of the HIV-1 CTL epitope DNA vaccine (EP1090) in HIV-1 infected…
- Trial name
- EP1090 (NCT00532974)
- Testing
- EP1090
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Epimmune
Hiv
Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients
A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive…
- Trial name
- NCT06560489
- Testing
- Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
HIV Infections
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle…
- Trial name
- NCT00002414
- Testing
- CPI-1189
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Centaur Pharmaceuticals
HIV Infections
A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
- Trial name
- NCT00002430
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- 46 sites in United States
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
- Trial name
- NCT00002236
- Testing
- Indinavir sulfate, Delavirdine mesylate, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pharmacia and Upjohn
HIV Infections
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
PART I: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of three fixed doses of delavirdine mesylate (DLV) in combination with zidovudine (AZT) versus AZT alone in HIV-positive patients.
- Trial name
- NCT00002124
- Testing
- Delavirdine mesylate, Lamivudine, Zidovudine
- Where
- 88 sites in United States, Puerto Rico
- Volunteers
- 1,250 people
- Sponsor
- Pharmacia and Upjohn
HIV Infections
A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC).
- Trial name
- NCT00002400
- Testing
- Indinavir sulfate, Delavirdine mesylate, Lamivudine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Pharmacia and Upjohn
HIV Infections
Atazanavir for HIV Infected Individuals: An Early Access Program
The purpose of this clinical research study is to provide atazanavir to patients infected with human immunodeficiency virus (HIV) whose antiviral medications are no longer working to control HIV activity within the body and who…
- Trial name
- NCT00046345
- Testing
- Atazanavir (BMS-232632)
- Where
- 165 sites in United States, Puerto Rico
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients
To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an…
- Trial name
- NCT00002435
- Testing
- Thymic Humoral Factor, Zidovudine
- Where
- 10 sites in United States
- Sponsor
- Pharmacia
HIV-1-infection
ART First-line Treatment Durability in Russia
This study is a non-interventional retrospective study. Data from patients who signed informed consent form will be collected through retrospective chart or medical records review.
- Trial name
- NCT04253119
- Testing
- Antiretroviral/Anti HIV
- Where
- 4 sites in Russia
- Volunteers
- 536 people
- Sponsor
- MSD Pharmaceuticals LLC
HIV Infections
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals
The purpose of this research study is to determine which of three different dose combinations of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is most effective and safe.
- Trial name
- NCT00034866
- Testing
- Protease inhibitor tipranavir
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 165 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
The purpose of this study is to see if it is safe and effective to give indinavir plus ritonavir plus 2 NRTIs to HIV-infected patients who need early intervention treatment.
- Trial name
- NCT00005118
- Testing
- Indinavir sulfate, Ritonavir
- Where
- 40 sites in United States
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals
To investigate the safety and tolerance of an increasing number of infusions per week of alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when administered to HIV-1-infected individuals.
- Trial name
- NCT00002087
- Testing
- Alvircept sudotox
- Where
- United States
- Sponsor
- Pharmacia and Upjohn
HIV
Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
This 48 week study is designed to compare the substitution of the thymidine analogues zidovudine (ZDV) or stavudine (D4T) with either tenofovir DF or abacavir, in patients treated with highly active antiretroviral therapy…
- Trial name
- NCT00270556
- Testing
- tenofovir disoproxil fumarate, Abacavir
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences